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Summary
Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, 
was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs 
at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we 
used the King’s clinical staging system to do a retrospective analysis of data from the original dose-ranging clinical trial 
of riluzole.
Methods In the original dose-ranging trial, patients were enrolled between December, 1992 and November, 1993, in 
Belgium, France, Germany, Spain, Canada, the USA, and the UK if they had probable or definite ALS as defined by 
the El Escorial criteria. The censor date for the riluzole survival data was set as the original study end date of 
Dec 31, 1994. For this analysis, King’s clinical ALS stage was estimated from the electronic case record data of the 
modified Norris scale, UK Medical Research Council score for muscle strength, El Escorial category, vital capacity, and 
gastrostomy insertion data. The lowest allocated stage was 2 because the original trial only included patients with 
probable or definite ALS. We used a χ² test to assess the independence of stage at trial enrolment and treatment 
group, Kaplan-Meier product limit distribution to test the transition from each stage to subsequent stages, and Cox 
regression to confirm an effect of treatment group on time in stage, controlling for covariates. We did sensitivity 
analyses by combining treatment groups, using alternative strategies to stage, stratifying by stage at trial enrolment, 
and using multistate outcome analysis of treatments (MOAT).
Findings We analysed the case records of all 959 participants from the original dose-ranging trial, 237 assigned to 
50 mg/day riluzole, 236 to 100 mg/day, 244 to 200 mg/day, and 242 to daily placebo. Clinical stage at enrolment did 
not significantly differ between treatment groups (p=0·22). Time in stage 4 was longer for patients receiving 
100 mg/day riluzole than for those receiving placebo (hazard ratio [HR] 0·55, 95% CI 0·36–0·83; log-rank p=0·037). 
Combining treatment groups and stratifying by stage at enrolment showed a similar result (HR 0·638, 95% CI 
0·464–0·878; p=0·006), as did analysis with MOAT where the mean number of days spent in stage 4 was numerically 
higher for patients given riluzole at higher doses compared with patients receiving placebo. Time from stages 2 or 3 
to subsequent stages or death did not differ between riluzole treatment groups and placebo (p=0·83 for stage 2 and 
0·88 for stage 3).
Interpretation We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be 
confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which 
benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future 
ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other 
neurodegenerative diseases.
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and the King’s Summer Undergraduate Studentship.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neuro­
degenerative disorder of upper and lower motor neurons 
that causes progressive paralysis and eventually death 
from respiratory failure.1 The course of ALS varies 
substantially between people, so that although median 
survival from symptom onset is only  27·5 months for 
those with bulbar onset (IQR 19·8–39·5) and 35·9 
months (22·9–56·4) for those with spinal onset,2 the 
range of survival length is wide, sometimes more than 
20 years. This variability complicates the analysis of 
clinical trials, since time is used as a proxy for disease 
progression, but the wide variation means that in some 
people there will have been little change, which 
potentially reduces the power to detect an effect of 
treatment. To mitigate this variability, most ALS trials 
have strict entry criteria that aim to exclude the most 
slowly progressing patients. Disease staging is another 
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approach, because it provides a framework for measuring 
disease progression regardless of whether the disease is 
aggressive or slow in any one individual. Several methods 
of staging ALS have been proposed, but the most widely 
used systems are the Milano­Torino functional staging 
system3 and the King’s clinical staging system,4 both of 
which can be derived from standard clinical observations.
King’s clinical stages range from 1 (early disease) to 
4 (late disease), with stage 5 being death. The state of the 
patient’s motor system is assessed using the El Escorial 
criteria domains of bulbar, upper limb, and lower limb.5 
Stages 1, 2, and 3 correspond to involvement of one, two, 
or three domains respectively, as evidenced by symptoms 
or examination findings. Stage 4 corresponds to 
nutritional failure (10% of premorbid weight loss because 
of dysphagia), or substantial respiratory failure (fulfilling 
guidelines for needing non­invasive ventilation). King’s 
stage can be estimated from the revised ALS functional 
rating scale (ALSFRS­R) with a high cor respondence to 
actual clinical stage, making it useful for retrospective 
analyses.6,7 King’s clinical staging system has been 
validated by confirmation in several populations and by 
correlation with biomarkers, and has been used to assess 
the timing of cognitive changes in ALS and for health­
economics analyses.8
Riluzole, a glutamatergic antagonist, is the only 
disease­modifying treatment shown to extend life in 
patients with ALS, associated with a 38·6% reduction 
in mortality in an efficacy trial9 and a 35% improvement 
in survival with the 100 mg dose in a dose­ranging 
trial.10 Riluzole has not shown an apparent effect on 
function, but any functional effect is difficult to assess 
in an ALS clinical trial because patients with the worst 
function tend to drop out of the study,11 either because 
travel becomes too onerous, or through death. As a 
result, only patients with relatively preserved function 
remain, which reduces the statistical power to detect an 
effect between treatment groups. A key question 
therefore is whether riluzole extends life throughout 
the course of ALS, or only at an early or late stage of the 
disease. From a patient’s perspective, there is a major 
difference between a drug that prolongs the early 
disease stages and a drug that prolongs later disease 
stages. From a health­economics standpoint, a survival 
benefit from extending early stages of disease might be 
preferable to prolongation at later stages where 
management of symptoms can be more expensive.7 To 
understand the relationship between the survival 
benefit of riluzole and disease stage, we retrospectively 
did a clinical staging analysis of results from the 
original dose­ranging study of riluzole.10
Methods
Participants and data collection
Patients in Belgium, France, Germany, Spain, Canada, 
the USA, and the UK with probable or definite ALS as 
defined by the El Escorial criteria were eligible for the 
original riluzole dose­ranging study, and enrolled 
between December, 1992 and November, 1993.10 In this 
retrospective analysis, we extracted data from the 
electronic case record forms of that study. The censor date 
for the riluzole survival data was set as the original study 
end date, Dec 31, 1994. To exclude an artefactual 
explanation for the findings, patient case record data 
from a trial of lithium carbonate in ALS (LiCALS; 
ISRCTN 83178718) was also tested for comparison.12
In this analysis, we staged participants retrospectively 
from the clinical trial data collected at each study visit 
Research in context
Evidence before this study
It is important to know whether the survival benefit of riluzole 
in patients with amyotrophic lateral sclerosis (ALS) occurs early, 
late, or throughout the course of the disease to enable proper 
counselling of patients. We searched PubMed for reports 
published at any date up to July 31, 2017, using the terms 
“riluzole”; “amyotrophic lateral sclerosis”, “motor neuron 
disease”, “motor neurone disease”, “ALS”, or “MND”; and “stage” 
or “staging”. We included randomised, placebo-controlled trials 
in patients with ALS that involved riluzole alone and studies of 
clinical staging in ALS. We identified two trials, both of which 
were randomised, placebo-controlled studies and one of which 
included sufficient data for retrospective staging. We 
approached the commercial owners of the riluzole clinical trial 
data for full academic access to the trial database.
Added value of this study
By use of the King’s clinical ALS staging system, we showed in a 
retrospective analsysis that riluzole prolonged stage 4 ALS in a 
dose-dependent manner, with no apparent prolongation of 
stage 2 or 3. We were unable to determine if there was an effect 
on stage 1.
Implications of all the available evidence
The timing of any benefit from riluzole affects the 
information that needs to be given to patients, because they 
are likely to interpret the benefit of prolongation of a later 
stage of disease as different from the benefit of prolonging an 
early stage, or prolongation of the disease course in general. 
The timing of benefit also has implications for health 
economics because the later stages of ALS are associated with 
higher costs than earlier stages, and therefore prolonging 
stage 4 is more costly than prolonging stages 1 or 2. Further 
studies are needed to determine if there is a survival benefit 
of riluzole in stage 1 ALS, and staging analyses should be used 
in future clinical trials of treatments in patients with ALS and 
other neurodegenerative diseases.
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using an algorithm. For the LiCALS study, an algorithm 
based on the ALSFRS­R had a correlation of 92% with 
actual clinical stage.6 However, the riluzole dose­ranging 
study data were collected before the ALSFRS­R had been 
developed, and we therefore used the same principles to 
develop a corresponding algorithm based on functional 
scores from electronic case­records to assign King’s clinical 
staging. Affected domains were established following 
specific criteria (appendix), using questions on the 
modified Norris scales, UK Medical Research Council 
muscle strength scores, El Escorial category, gastrostomy 
data, and vital capacity. Tracheostomy and intubation were 
classified as equivalent to death for the purposes of 
analysis. Allocation to stage 4 requires either nutritional 
failure sufficient to require gastrostomy, or respiratory 
failure sufficient to require non­invasive ventilation. We 
therefore used insertion of gastrostomy, or a vital capacity 
of 75% or less than predicted, as proxy markers of stage 4. 
The vital capacity threshold was selected on the basis of 
thresholds used in previous studies 13,14 and UK national 
guidelines.15 Because clinical stage was being estimated, 
and previous studies have not shown transition from later 
stages back to earlier stages, we maintained the highest 
stage recorded if a subsequent estimate of stage showed an 
apparent reversal. The lowest allocated clinical stage was 
stage 2 as the original trial consisted only of patients with 
El Escorial probable or definite ALS, and the analysis was 
therefore unable to answer questions about the effect of 
riluzole at stage 1 ALS. All enrolled patients provided 
informed consent for participation in the original clinical 
study and for use of the data collected for subsequent 
analyses. Ethics approval for the original trial was granted 
by the local or national independent ethics committee of 
each participating centre.
Statistical analysis
Because stage at enrolment might differ between 
treatment groups and therefore affect analysis, we did a 
χ² test of the independence of stage at enrolment and 
treatment group. To test the hypothesis that the benefit of 
riluzole treatment would be seen in all disease stages, we 
estimated the mean duration of each stage for each 
treatment group. We used the Kaplan­Meier product limit 
distribution to compare treatment groups for the time 
taken to change stage. The test was repeated, stratifying 
for stage at enrolment, and limited to partici pants entering 
at stage 2 or 3. We used Cox regression to confirm any 
finding of an effect of treat ment group on time in clinical 
stage, controlling for covariates. Regression models were 
built step wise, adding in stage at entry; an interaction 
term for treatment group and clinical stage at entry; age, 
and sex, with covariates discarded if the model fit was not 
significantly improved.
We did several sensitivity analyses to ensure that the 
findings were robust. Kaplan­Meier analyses were 
repeated after combining riluzole treatment groups, either 
using the doses shown to significantly improve survival in 
the original efficacy trial (100 mg/day and 200 mg/day), 
using current treatment recommendations (100 mg per 
day), or using all tested doses (50 mg/day, 100 mg/day, 
and 200 mg/day), and with alternative vital capacity 
thresholds to define stage 4 of 70% or less and 80% or less 
of predicted. Since King’s staging has not previously been 
used to estimate the timing of benefit, we also did the 
same analyses for the LiCALS data to exclude an artefact 
in trial data as a basis for the findings. To confirm the 
results were not an artefact of the analysis method, we 
also used a second approach, Multistate Outcome Analysis 
of Treatment (MOAT).16 MOAT does not tolerate missing 
data, and we therefore imputed missing or superseded 
disease stages by using the mean stage duration 
proportion by treatment groups across the study. Statistical 
tests were done using IBM SPSS Statistics 24.0, RStudio 
1.0.143, R Foundation for Statistical Computing 3.4.1, and 
SAS 9.4. Original data from the riluzole trial can be 
accessed by application to Sanofi.
Role of the funding source
The funders of the study had no role in study design and 
data collection, data analysis, data interpretation, or 
writing of the report. The cor responding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
We obtained data for all 959 patients assigned to 
treatment with case records from the original dose­
ranging study; 237 assigned to riluzole 50 mg/day, 
236 to 100 mg/day, 244 to 200 mg/day, and 242 to daily 
placebo. Three people were recorded as not taking trial 
medication, one assigned to 50 mg/day riluzole and 
two to 100 mg/day. 355 patients were enrolled at ALS 
stage 2, 451 at stage 3, and 153 at stage 4. Stage at 
enrolment did not differ between treatment groups 
(p=0·22; appendix). Counting the same patient at 
multiple stages where necessary, 355 patients reached 
Stage 2 Stage 3 Stage 4
Time transitioning to a later stage or death
50 mg/day riluzole 256 (152) 241 (138) 224 (158)
100 mg/day riluzole 243 (161) 265 (150) 248 (180)
200 mg/day riluzole 243 (156) 230 (143) 233 (154)
Placebo 223 (157) 248 (143) 233 (154)
Time maintaining the same stage over the trial
50 mg/day riluzole 570 (92) 492 (158) 404 (256)
100 mg/day riluzole 560 (88) 491 (160) 490 (230)
200 mg/day riluzole 576 (103) 450 (169) 507 (240)
Placebo 568 (90) 485 (170) 391 (288)
Data are mean (SD) times in days. Mean time spent was calculated per patient and 
averaged over all patients in that group.
Table 1: Stage transition times for amyotrophic lateral sclerosis with 
riluzole or placebo
See Online for appendix
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stage 2, 678 reached stage 3, and 306 reached stage 4. 
Although there were no differences between treatment 
groups in the mean time spent transitioning to a later 
stage (table 1), time spent in stage 4 was longer for 
patients not transitioning who were receiving 100 mg/day 
riluzole than for those not transitioning who were 
receiving placebo (log­rank p=0·037; figure 1). 
Stratification by stage at enrolment using Kaplan­Meier 
analysis did not change this result (p=0·027). Results 
remained largely unchanged when the analysis was 
limited to those enrolling at stages 2 or 3 (appendix). 
Time from stages 2 or 3 to subsequent stages or death 
did not differ significantly between treatment groups and 
placebo, (figure 1).
Restricting the Kaplan­Meier analysis to the 
recommended treatment dose for riluzole of 100 mg/day 
still showed an extension of stage 4 (hazard ratio [HR] 
0·53, 95% CI 0·35–0·81; p=0·003), which persisted after 
stratifying by stage at enrolment (p=0·003). Cox regression 
confirmed an effect of treatment group on time in stage 4 
(p=0·009; table 2), independent of the effect of clinical 
stage at entry (p<0·0001) with no evidence for an effect of 
the interaction of treatment group and stage at entry, age, 
or sex. The findings were the same if treatment groups 
were tested in combination (treatment group p=0·006, 
stage at entry p<0·0001), or restricted to the recom mended 
treatment dose of 100 mg per day (treatment group 
p<0·0001, stage at entry p<0·0001; table 2).
Combining treatment groups did not change these 
results. Analysing all treatment groups as a whole against 
placebo showed a significant prolongation of stage 4 in 
the treatment groups (HR 0·66, 95% CI 0·48–0·91; 
p=0·01), as did limiting the analysis to the two higher 
doses against placebo (figure 2), but there was no 
prolongation for other stages (figure 2). Altering the vital 
capacity threshold defining stage 4 to 80% or less did not 
change the findings (p=0·014), although reducing it to 
70% or less of predicted meant that only 39 patients 
fulfilled respiratory criteria for stage 4 and the effect of 
prolonging stage 4 with treatment was no longer evident 
(HR 50 mg vs placebo 0·84 [0·51–1·37], 100 mg vs placebo 
0·60 [0·36–1·00], 200 mg vs placebo 0·67 [0·42–1·08]; 
p=0·18). The findings were unchanged when treatment 
groups were combined, regardless of the definition of 
stage 4: for vital capacity of 70% or less than predicted, 
higher doses versus placebo HR 0·64 (95% CI 0·47–
1·03), p=0·037, all doses versus placebo 0·69 (0·42–
0·98), p=0·067; for vital capacity of 80% or less than 
predicted, higher doses versus placebo 0·66 (0·51–0·86), 
p=0·002, all doses versus placebo 0·68 (0·54–0·87), 
p=0·002. 
To exclude an artefactual explanation for findings, we 
did comparison tests using data from the LiCALS trial in 
which all 217 participants entered at stage 1, of which 
214 were randomly assigned, 107 to treatment and 107 to 
placebo. Treatment with lithium did not prolong the 
duration of any stage (for stage 1, HR 1·00, 95% CI 0·84–
1·19, p=0·98; stage 2, 1·04, 0·83–1·30, p=0·73, stage 3, 
1·40, 0·96–2·04, p=0·082, and stage 4, 1·51, 0·74–3·05, 
p=0·25. MOAT analysis confirmed the findings of the 
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Figure 1: Patients progressing from each stage of amyotrophic lateral sclerosis with riluzole or placebo
(A) Treatment with 100mg riluzole per day significantly prolonged time in stage 4 compared with placebo 
(p=0·037). (B) Treatment with all doses did not prolong time in stage 2 compared with placebo (p=0·83). (C) 
Treatment with all doses did not prolong time in stage 3 compared with placebo (p=0·88). HR=hazard ratio.
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Kaplan­Meier approach, showing that those treated with 
riluzole had a longer stage 4 than those on placebo 
(table 3).
Discussion
Treatment with riluzole prolonged stage 4 in patients 
with ALS. This result was robust to the method of 
analysis and independent of the stage at which 
treatment was started. This finding implies that the 
survival benefit of riluzole is achieved by extending 
stage 4, not by prolonging stages 2 or 3, or generally 
slowing disease.
Patients counselled about riluzole are told that it 
extends life, but not at which stage, since this was not 
clear from the original study.10 One analysis suggested 
Hazard ratio 95% CI p value
Individual treatment groups
Treatment effect overall ·· ·· 0·009
50 mg/day riluzole compared 
with placebo
0·742 (0·501–1·100) 0·138
100 mg/day riluzole 
compared with placebo
0·480 (0·313–0·735) 0·001
200 mg/day riluzole 
compared with placebo
0·710 (0·481–1·048) 0·085
Stage at entry effect overall ·· ·· <0·0001
Entry at stage 2 compared 
with 4
1·697 (1·063–2·709) 0·027
Entry at stage 3 compared 
with 4
2·966 (2·118–4·152) <0·0001
Combined treatment groups compared with placebo
Treatment at any dose 
compared with placebo
0·638 (0·464–0·878) 0·006
Stage at entry effect overall ·· ·· <0·0001
Entry at stage 2 compared 
with 4
1·664 (1·043–2·655) 0·033
Entry at stage 3 compared 
with 4
2·825 (2·026–3·939) <0·0001
Recommended treatment dose compared with placebo
100 mg/day riluzole 
compared with placebo
0·456 (0·295–0·704) 0·0004
Stage at entry effect overall ·· ·· <0·0001
Entry at stage 2 compared 
with 4
2·034 (1·031–4·016) 0·041
Entry at stage 3 compared 
with 4
3·154 (1·957–5·080) <0·0001
Combined higher treatment doses compared with placebo
100 mg/day or 200 mg/day 
riluzole compared with 
placebo
0·578 (0·409–0·816) 0·002
Stage at entry effect overall ·· ·· <0·0001
Entry at stage 2 compared 
with 4
2·268 (1·357–3·790) 0·002
Entry at stage 3 compared 
with 4
3·023 (2·055–4·447) <0·0001
Data analysed by Cox regression. Variables were included step-wise in the model 
and removed if there was no significant improvement in the model fit. The 
variables tested were treatment group; stage at trial entry; interaction between 
treatment group and stage at trial entry; age; and sex. Only treatment group and 
stage at trial entry were retained in the model.
Table 2: Effect of variables on time spent in stage 4 amyotrophic lateral 
sclerosis
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Figure 2: Patients progressing from each stage of amyotrophic lateral sclerosis with 100 mg plus 200 mg 
riluzole or placebo
(A) Treatment with higher doses significantly prolonged time in stage 4 compared with placebo (p=0·006). 
(B) Treatment with higher doses did not prolong time in stage 2 compared with placebo (p=0·99). (C) Treatment 
with higher doses did not prolong time in stage 3 compared with placebo (p=0·86). HR=hazard ratio.
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that benefit might occur while function is well preserved,17 
but the dose­ranging riluzole trial showed no overall 
effect on function,10 which led to the conundrum of how 
to explain an improvement in survival without a 
concomitant effect on function. Our finding that the 
extension of life is due to an extension of stage 4 helps to 
resolve this confusion, since function at this stage is 
limited, and a flattening of the slope of functional decline 
would be hard to detect. Furthermore, the ALSFRS­R 
slope change with time is curvilinear and therefore 
flattens at the beginning and end.18 Although the timing 
might seem undesirable since the prolongation of life is 
when disability is high, rather than when the patient is 
functionally well, all other current treatments that extend 
life act at the last stage of disease. Non­invasive ventilation 
for example, has been shown to prolong life and improve 
quality,19 and is used at stage 4. The take­up of non­
invasive ventilation is high among patients,20 suggesting 
that prolongation of life at later stages of disease is not 
undesirable in itself, and riluzole is well tolerated in 
advanced ALS.21 Similarly, gastrostomy is used to support 
those with nutritional failure due to dysphagia, improving 
quality of life,22 and also is applied at stage 4. 
A direct clinical implication of our findings is that 
patients can be told that riluzole extends the later stages 
of ALS, but it is important to note that it might also 
extend stage 1, since we have no information on this 
stage from the trial data.
Riluzole could act through several mechanisms; eg, on 
excitotoxic pathways early in the course of ALS, and 
through effects on mitochondrial function, fat metabolism, 
or diaphragmatic strength that might be more crucial to 
survival later. A specific benefit of riluzole therapy in 
patients with reduced vital capacity is supported by 
statistical model­based analysis of clinical trial data.23 
When riluzole was first identified as a beneficial treatment 
for ALS, its use in various health­care systems was 
controversial because the survival benefit was seen as 
small, while the drug cost was seen as high. A combination 
of health­economics analyses and pressure from patient 
groups led to its widespread adoption,24 although in some 
countries approval was delayed. In the UK, the National 
Institute for Health and Clinical Excellence approved 
riluzole for ALS following a detailed cost­benefit analysis 
that included the concept of quality­adjusted life­years.25,26 
Although our finding of a prolongation of stage 4 might 
affect such analyses, riluzole is no longer on patent; it is 
now cheaper than it was when the initial health economics 
analyses were done, and cheaper than other treatments for 
ALS, such as edaravone [A: please add a reference here].
A strength of our study was the use of clinical staging to 
analyse clinical trial data in a neurodegenerative disease, 
allowing an examination of when benefit occurs in a way 
that is easily understood by clinicians and patients. Thus, 
as an outcome measure, clinical staging has an important 
part to play in future trial design in ALS and other 
neurodegenerative diseases. In cancers, another group of 
diseases which if untreated lead to progressive disability 
and death, trials routinely use staging to decide on the 
appropriate treatment and to assess outcome.27 A further 
benefit of staging is that successful treatments can be 
shown to reverse the progression through clinical stages.
There were several important weaknesses of this study. 
It was a post­hoc analysis, and therefore did not provide 
the same level of evidence as a prespecified analysis, 
since the study design did not consider staging in the 
calculation of statistical power or in the assessment 
criteria. Furthermore, the criteria for stage 4 mean that 
153 (16%) of the 959 patients were in stage 4 at enrolment. 
This would not usually be the case in a modern trial in 
ALS given the stringent criteria commonly used now 
(eg, forced vital capacity of ≥80%). However, our findings 
were similar when these 153 patients were excluded in a 
further analysis. Clinical stage was estimated from trial 
data. We have previous experience in this process, and 
have successfully applied an algorithm to the ALSFRS­R 
to derive clinical stage.6 In this study, we could not use 
the ALSFRS­R because such a scale did not exist when 
the trial data were collected; as a result, we had to 
generate a new algorithm to estimate clinical stage. 
There was no way to validate this new algorithm, since 
one of the scales it used, the Norris scale, is no longer in 
use. To overcome this, we applied the same logical 
process to the data that was used to generate the 
ALSFRS­R algorithm for staging. Further more, adjusting 
the criteria defining the clinical stages did not change the 
findings of the study, and using two entirely different 
analytical approaches generated the same conclusions.
A further limitation of this study arose from the strict 
inclusion criteria of the original trial, which was restricted 
to people fulfilling El Escorial criteria for probable or 
definite ALS.10 This prevented our study from analysing 
the treatment effects of riluzole in stage 1 of disease. 
However, some studies have suggested that the effects of 
riluzole might be transient,28–30 and support treatment in 
the early stages of ALS.29 To determine whether riluzole 
extends stage 1 will require a specific trial. Additionally, 
patients’ weight was not recorded at each visit in the 
original study and therefore the nutritional component of 
the stage 4 definition was inferred from the date of 
gastrostomy. Our findings therefore need to be validated in 
a future trial with regular recording of weight. Although it 
50 mg/day 
riluzole
100 mg/day 
riluzole
200 mg/day 
riluzole
Placebo
Stage transition
2–3 109 (99–118) 70 (60–81) 100 (89–110) 82 (72–91)
3–4 38 (29–48) 52 (43–61) 30 (23–37) 69 (61–78)
4–5 207 (195–219) 234 (222–246) 226 (215–237) 198 (186–209)
Data are the mean number of days (95% CI), presented by treatment group. 
Table 3: Multistate outcome analysis of treatment analysis of time to 
transition from one stage of amyotrophic lateral sclerosis to the next
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is ethically difficult to do new studies exclusively of riluzole, 
studies of this drug embedded within other clinical trials 
have been completed (eg, the study of dexpramipexole in 
ALS; EMPOWER, NCT01281189),31 or are underway (eg, a 
study of low­dose interleukin­2 in ALS; MIROCALS, 
NCT03039673). Such an approach could potentially 
address our findings within a prospective study design, or 
retrospectively confirm these findings using similar 
techniques to ours within existing data.
Riluzole is currently the only treatment shown to 
prolong life in patients with ALS. We have shown that it 
acts by prolonging stage 4 ALS rather than by slowing the 
entire disease course or prolonging intermediate stages. 
Similar methods should be used in future clinical trials 
of ALS or other neurodegenerative diseases where 
survival is an endpoint, to show where benefit is accrued 
and to allow a full discussion of effects when counselling 
patients about treatment.
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